{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:26:04Z","timestamp":1783416364635,"version":"3.54.6"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,22]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Osteoarthritis (OA) is increasingly recognized as a condition with a distinct metabolic phenotype, characterized by systemic low-grade inflammation and metabolic dysregulation. Concurrent with the rising prevalence of OA is the global burden of metabolic dysfunction-associated steatotic liver disease. This study aimed to evaluate and compare the associations of 3 noninvasive liver scores \u2013 hepatic steatosis index (HSI), NAFLD fibrosis score (NFS), and Fibrosis-4 index (FIB-4) \u2013 with OA prevalence among US adults. We performed a cross-sectional analysis of National Health and Nutrition Examination Survey cycles (1999\u20132018). HSI, NFS, and FIB-4 were calculated and examined both as quartiles and per standard deviation increment. Associations with self-reported OA were estimated using survey-weighted modified Poisson regression with robust variance (prevalence ratios) as the primary approach, with survey-weighted logistic regression (odds ratios) performed as a secondary analysis. The final sample included 40,447 participants. In fully adjusted Poisson regression models (Model 3), HSI demonstrated the most robust and consistent association with OA. Participants in the highest HSI quartile exhibited a 2.09-fold higher OA prevalence compared with the lowest quartile, with a dose\u2013response relationship. NFS demonstrated a moderate association, though substantially attenuated compared with its crude estimate after adjustment for demographic, socioeconomic, lifestyle, and non-embedded clinical covariates. Notably, the association between FIB-4 and OA was largely confounded by age; after adjustment, FIB-4 showed only a modest association in the highest quartile, whereas the continuous association was null. Sensitivity analyses consistently showed that HSI had the strongest and most stable association with OA among the 3 indices. The steatosis-oriented metabolic burden reflected by HSI shows a stronger adjusted association with OA than the more age-dependent fibrosis marker FIB-4 in the general population. These results support the view that steatosis-related metabolic dysfunction may be more relevant to OA burden than hepatic fibrotic burden alone. Because HSI incorporates body mass index and diabetes status, the observed association should be interpreted as that of a composite metabolic marker rather than a fully independent effect of hepatic steatosis itself. HSI may therefore be useful as a simple indicator of a steatosis-oriented metabolic OA profile in integrated risk assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048764","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T17:00:32Z","timestamp":1779469232000},"page":"e48764","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic liver burden and osteoarthritis prevalence: A comparative analysis of noninvasive hepatic indices"],"prefix":"10.1097","volume":"105","author":[{"given":"Di","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Orthopedics, The First Hospital of China Medical University, Shenyang, Liaoning Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3269-0391","authenticated-orcid":false,"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Geratology, The First Hospital of China Medical University, Shenyang, Liaoning Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260707","doi-asserted-by":"crossref","first-page":"1476853","DOI":"10.3389\/fmed.2024.1476853","article-title":"Global, regional, and national burdens of osteoarthritis from 1990 to 2021: findings from the 2021 global burden of disease study.","volume":"11","author":"Li","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"R2-20260707","doi-asserted-by":"crossref","first-page":"1759720X241273009","DOI":"10.1177\/1759720X241273009","article-title":"Knee osteoarthritis: disease burden, available treatments, and emerging options.","volume":"16","author":"Langworthy","year":"2024","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R3-20260707","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/1573397117666211116111738","article-title":"Emerging and new treatment options for knee osteoarthritis.","volume":"18","author":"Siddiq","year":"2022","journal-title":"Curr Rheumatol Rev"},{"key":"R4-20260707","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2018-213864","article-title":"Deep phenotyping of osteoarthritis: a step forward.","volume":"78","author":"Berenbaum","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R5-20260707","doi-asserted-by":"crossref","first-page":"1759720X20937966","DOI":"10.1177\/1759720X20937966","article-title":"Setting up distinctive outcome measures for each osteoarthritis phenotype.","volume":"12","author":"Roman-Blas","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R6-20260707","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.joca.2014.10.002","article-title":"Metabolic triggered inflammation in osteoarthritis.","volume":"23","author":"Wang","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"R7-20260707","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/jcp.25716","article-title":"Systemic and local adipose tissue in knee osteoarthritis.","volume":"232","author":"Belluzzi","year":"2017","journal-title":"J Cell Physiol"},{"key":"R8-20260707","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"R9-20260707","doi-asserted-by":"crossref","first-page":"1001281","DOI":"10.37349\/emed.2025.1001281","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management.","volume":"6","author":"Adinolfi","year":"2025","journal-title":"Explor Med"},{"key":"R10-20260707","doi-asserted-by":"crossref","first-page":"1433857","DOI":"10.3389\/fcell.2024.1433857","article-title":"Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.","volume":"12","author":"Sandireddy","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"R11-20260707","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3390\/biomedicines13051260","article-title":"Chronic inflammation and immune dysregulation in metabolic-dysfunction-associated steatotic liver disease progression: from steatosis to hepatocellular carcinoma.","volume":"13","author":"Jee","year":"2025","journal-title":"Biomedicines"},{"key":"R12-20260707","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/jcp.30593","article-title":"The molecular structure and role of LECT2 or CHM-II in arthritis, cancer, and other diseases.","volume":"237","author":"Zhu","year":"2022","journal-title":"J Cell Physiol"},{"key":"R13-20260707","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/antiox13010124","article-title":"The hepatokine RBP4 links metabolic diseases to articular inflammation.","volume":"13","author":"Pazos-P\u00e9rez","year":"2024","journal-title":"Antioxidants (Basel)"},{"key":"R14-20260707","doi-asserted-by":"crossref","first-page":"508","DOI":"10.23736\/S0031-0808.20.04171-3","article-title":"Non-invasive biomarkers in predicting non-alcoholic steatohepatitis and assessing liver fibrosis: systematic review and meta-analysis.","volume":"63","author":"Ismaiel","year":"2021","journal-title":"Panminerva Med"},{"key":"R15-20260707","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s10620-023-08186-8","article-title":"Limitations of noninvasive tests-based population-level risk stratification strategy for nonalcoholic fatty liver disease.","volume":"69","author":"Behari","year":"2024","journal-title":"Dig Dis Sci"},{"key":"R16-20260707","doi-asserted-by":"crossref","first-page":"166","DOI":"10.15171\/mejdd.2016.29","article-title":"New concepts on pathogenesis and diagnosis of liver fibrosis; a review article.","volume":"8","author":"Ebrahimi","year":"2016","journal-title":"Middle East J Dig Dis"},{"key":"R17-20260707","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43066-021-00115-6","article-title":"Validity of routine biochemical and ultrasound scores for prediction of hepatic fibrosis and steatosis in NAFLD.","volume":"11","author":"Eletreby","year":"2021","journal-title":"Egypt Liver J"},{"key":"R18-20260707","first-page":"360","article-title":"Comparison of hepatic steatosis index as noninvasive diagnostic tool and liver ultrasound for non-alcoholic steatosis in the adult population.","volume":"15","author":"Khani","year":"2022","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"R19-20260707","first-page":"270","article-title":"Interest of hepatic steatosis index (HSI) in screening for metabolic steatopathy in patients with type 2 diabetes.","volume":"37","author":"Fennoun","year":"2020","journal-title":"Pan Afr Med J"},{"key":"R20-20260707","doi-asserted-by":"crossref","first-page":"e0249","DOI":"10.1097\/HC9.0000000000000249","article-title":"Diagnostic performance of the fibrosis-4 index and the NAFLD fibrosis score for screening at-risk individuals in a health check-up setting.","volume":"7","author":"Park","year":"2023","journal-title":"Hepatol Commun"},{"key":"R21-20260707","doi-asserted-by":"crossref","first-page":"107684","DOI":"10.1016\/j.jdiacomp.2020.107684","article-title":"NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes.","volume":"34","author":"Lombardi","year":"2020","journal-title":"J Diabetes Complications"},{"key":"R22-20260707","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/1354750X.2018.1425915","article-title":"New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease.","volume":"23","author":"Tada","year":"2018","journal-title":"Biomarkers"},{"key":"R23-20260707","doi-asserted-by":"crossref","first-page":"ofae014","DOI":"10.1093\/ofid\/ofae014","article-title":"Risk stratification of advanced fibrosis in patients with human immunodeficiency virus and hepatic steatosis using the fibrosis-4, nonalcoholic fatty liver disease fibrosis, and BARD scores.","volume":"11","author":"Yendewa","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"R24-20260707","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s10787-021-00842-7","article-title":"Association between metabolic associated fatty liver disease and osteoarthritis using data from the Korean National Health and Nutrition Examination Survey (KNHANES).","volume":"29","author":"Han","year":"2021","journal-title":"Inflammopharmacology"},{"key":"R25-20260707","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13075-024-03272-2","article-title":"Association of non-alcoholic fatty liver disease with self-reported osteoarthritis among the US adults.","volume":"26","author":"Lu","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"R26-20260707","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s10238-026-02096-5","article-title":"Metabolic dysfunction-associated fatty liver disease and risk of knee osteoarthritis: a prospective cohort study.","volume":"26","author":"Zhang","year":"2026","journal-title":"Clin Exp Med"},{"key":"R27-20260707","first-page":"1","article-title":"National health and nutrition examination survey: analytic guidelines, 1999-2010.","volume":"2","author":"Johnson","year":"2013","journal-title":"Vital Health Stat"},{"key":"R28-20260707","first-page":"1","article-title":"National health and nutrition examination survey: sample design, 2011-2014.","volume":"2","author":"Johnson","year":"2014","journal-title":"Vital Health Stat"},{"key":"R29-20260707","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease.","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"R30-20260707","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"R31-20260707","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection.","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"R32-20260707","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis.","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R33-20260707","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.","volume":"75","year":"2021","journal-title":"J Hepatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:00:25Z","timestamp":1783414825000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":33,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048764","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2026-02-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}